Class Action Article

  • File A Talcum Powder Lawsuit: Talcum Powder Ovarian Cancer Lawsuits Talcum Powder Fallopian Tube Cancer Lawsuits Baby  Powder Ovarian Cancer Lawsuits Filed If you or a loved one used talcum powder products and were diagnosed with ovarian cancer, or fallopian tube can...

Class Action News

Drug Class Actions

  • Taxotere Lawyers for Permanent Hair Loss: Taxotere Baldness Lawyers For  Permanent Hair Loss Lawsuits Have you received Taxotere for breast cancer? Taxotere can result in hair loss or baldness  that is permanent. Taxotere  is a chemotherapy drug used for the treatment of breas...

Medical Device Lawsuits

  • Get A Hernia Mesh Lawyer | Hernia Mesh Lawsuits Filed: The hernia mesh lawyers of Class Action Lawyer Network are filing hernia mesh lawsuits for victims of a failed hernia mesh. We have Ethicon, Bard and Cook hernia mesh lawyers. Hernia Mesh Lawsuits Filed  For: Ethicon: Physiomesh Pro...

Posts Tagged ‘find an actos lawyer’

I Have Heard Actos Can Cause Bladder Cancer? Is That True? How Do I File An Actos Lawsuit

Written by lisaspitzer on . Posted in Actos Lawsuit Lawyers, Drug Warnings

Actos does have warnings for bladder cancer with use for extended periods of time. Actos lawyers are filing lawsuits for people who have developed bladder cancer as a part of a multi district litigation.

FDA Warnings For Actos and Bladder Cancer

FDA Drug Safety Communication: Update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer

Actos Bladder Cancer Safety Announcement

[6-15-2011] The U.S. Food and Drug Administration (FDA) is informing the public that use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer. Information about this risk will be added to the Warnings and Precautions section of the label for pioglitazone-containing medicines.

Actos Bladder Cancer Lawsuit

Actos lawsuits are being  filed on behalf of type II diabetics who developed bladder cancer from long-term use of the  drug Actos. These lawsuits continue to move forward in a multidistrict litigation in U.S. District Court, Western District of Louisiana. More than 2,500 Actos bladder cancer lawsuits are currently pending in the Western District of Louisiana, where the first trials are scheduled to begin in January.

Actos Product Liability Litigation, MDL No. 2299

If you believe you, a loved one or someone you are a caregiver for has gotten bladder cancer and has been on Actos call and speak to an Actos lawyer today. There must be a confirmed diagnosis of bladder cancer to be added to the lawsuit.

Actos Lawyers, Actos News, Actos Bladder Cancer Victims

Written by Class Action Lawyer on . Posted in Louisiana Multidistrict Litigation Lawyers

Actos has warnings for bladder cancer. Actos cases have been consolidated and Actos Lawyers are accepting clients.

The judge overseeing lawsuits alleging Takeda Pharmaceutical Co. (4502)’s Actos diabetes medicine causes cancer appointed 19 plaintiffs’ lawyers to manage litigation involving U.S. claims.

Takeda, Asia’s biggest drugmaker, may face as many as 10,000 claims that Actos causes bladder cancer after U.S. regulators found last year the drug was linked to the disease. Federal lawsuits against the drugmaker were consolidated before U.S. District Judge Rebecca Doherty in Lafayette, Louisiana, in December. The first hearing on the cases is set for March 22, according to court filings.

“The court has determined to effect the selection of lead counsel, liaison counsel and plaintiffs’ executive and steering committees before the March 22nd-23rd status conference,” Doherty said in a March 12 note posted on the court’s website.

The lawsuits claim patients who use Actos, a prescription drug approved to treat type 2 diabetes, face increased risks of developing bladder cancer. The plaintiffs also claim that Takeda and co-defendant Eli Lilly & Co., based in Indianapolis, withheld information about the risk and failed to provide adequate warnings.

Takeda pulled Actos, its top-selling drug, off the market in Germany and France last year after it was linked to an increased cancer risk. The medication had sales of 387.9 billion yen ($4.8 billion) last fiscal year, 27 percent of the Osaka, Japan-based company’s revenue.
Lead Counsel

“Given that litigation is pending, we can’t comment,” Jocelyn Gerst, a U.S.-based spokeswoman for Takeda, said in a telephone interview about the selection of the plaintiffs’ group.

Doherty named attorneys Richard Arsenault and Paul Pennock as lead plaintiffs’ counsel in the case and also appointed them to the executive committee, along with lawyers Mark Robinson and Hunter Shkolnik.

Arsenault, a products-liability lawyer based in Alexandria, Louisiana, served as one of the lead lawyers in consolidated cases filed against Merck & Co. (MRK) over its Vioxx painkiller that resulted in a $4.85 billion settlement in November 2007.

Pennock, a New York-based attorney, was one of the lawyers leading the consolidated suits against AstraZeneca Plc (AZN) over its Seroquel antipsychotic drug. The London-based drugmaker agreed last year to pay a total of about $350 million to resolve patients’ claims that the drug caused diabetes.
Steering Committee

The Los Angeles-based Robinson, who has won multimillion- dollar jury awards against carmakers such as Ford Motor Co., is a co-lead counsel in sudden-acceleration lawsuits against Toyota Motor Corp. (7203)

Shkolnik, based in New York City, served as a member of the plaintiffs’ steering committee in lawsuits against Medtronic Inc. (MDT) over flawed heart defibrillators. The cases later settled for more than $114 million.

Other lawyers named to the plaintiffs’ steering committee in the Actos cases include Mark Lanier, a Texas-based lawyer who won the first jury award against Whitehouse Station, New Jersey- based Merck in the Vioxx litigation, and Chris Seeger, a New Jersey-based attorney who also won a verdict against Merck on behalf of Vioxx users.

The judge also named Andy Birchfield, an Alabama-based lawyer who helped negotiate the $4.85 billion Vioxx settlement, and Vance Andrus, a Lafayette-based lawyer who was one of the lead counsels in cases against GlaxoSmithKline Plc (GS) over its Avandia diabetes drug. The London-based drugmaker has agreed to pay more than $700 million to resolve claims that Avandia caused heart attacks and strokes in users.

The lawsuits are consolidated in In Re: Actos Products Liability Litigation, 11-2299, U.S. District Court, Western District of Louisiana (Lafayette).

Lawyers Still Accepting Actos Cases, Actos Causing Bladder Cancer

Written by Class Action Lawyer on . Posted in Class MDL Class Action News

Lawyers Still Accepting Actos Cases as First Hearing Set to Begin. If you or a loved one has been diagnosed with bladder cancer from Actos contact us for an Actos lawyer today.

10,000 Actos lawsuits are expected to be filed
Orlando, FL (PRWEB) February 21, 2012
A federal judge tasked with overseeing the litigation over whether a popular diabetes drug caused bladder cancer in hundreds of patients is moving quickly to expedite the legal process for both sides.
While those who have already filed an Actos lawsuit are one step closer to having their day in court, lawyers are still helping those who are just coming forward with side effects.
On Monday, February 13, U.S. District Judge Rebecca Doherty issued an order scheduling a pretrial status conference in the Actos litigation for March 22, 2012. The hearing will give representatives of the drug manufacturer and those of patients alleging bladder cancer from the drug a chance to discuss trial preparation and whether any progress has been made in reaching a settlement.
After the hearing, Judge Doherty will also appoint lead counsel in the consolidated cases from her bench in Lafayette, Louisiana.
Doherty was originally assigned to dozens of the lawsuits in Multi-District Litigation following an order by the U.S. Judicial Panel on Multidistrict Litigation in December. She now presides over approximately 150 cases and lawyers expect thousands more may be filed before litigation is complete. The pending case is In Re: Actos Products Liability Litigation, MDL 2299, U.S. District Court, Western District of Louisiana (Lafayette).
Lawyers with the Actos Resource Center have responded to hundreds of inquiries from those who have taken Actos and expect many more will come forward due to the popularity of the drug.
On June 15, 2011, the FDA issued a warning that taking Actos for longer than one year could heighten the risk of bladder cancer. Approved by the FDA in 1999, Actos had become one of the most popular diabetes drugs in the world after rival Avandia was linked to heart problems.
The warning came after a study of 155,000 patients over four years by the French Medicines Agency showed taking Actos could increase the occurrence of bladder cancer by up to 40%.
Authorities in France and Germany quickly banned sales of the drug. However, it remains on the market in the United States.
Now, according to a Bloomberg article published December 1, 2011, drug makers Takeda Pharmaceuticals and Eli Lilly could face as many as 10,000 lawsuits from those stricken with bladder cancer after taking Actos.
On Tuesday, Takeda released a statement saying "Takeda is confident in the therapeutic benefits of Actos and its importance as a treatment for type 2 diabetes. As a science and evidence-based company, Takeda firmly stands behind the substantial data available confirming the positive risk/benefit profile of Actos, which includes twelve years of clinical and patient experience with the product."
For more information on the side effects, FDA warnings and litigation associated with Actos, visit ActosCancer.com.

Class Action Lawyer Netrwork Actos Lawyers are accepting cases for bladder cancer form Actos. These are part of an Actos Multi District litigation.

New News on Actos, Takeda Named In Actos Lawsuits

Written by Class Action Lawyer on . Posted in Class MDL Class Action News

Takeda named in suits over use of diabetes drug Actos
2/2/2012 7:32 AM By Andrea Dreaden

 

Three Illinois couples have filed lawsuits claiming the manufacturers of a diabetes medication knew the drug caused cancer but intentionally hid that from patients.

Donald E. and Sharon Sandidge, of Alton, Phillip A. and Mickey Block, of Rinard, and John L. and Sandra Allen, of Washington, each filed complaints Jan. 18 in Madison County Circuit Court against Takeda Pharmaceuticals America Inc., Takeda Pharmaceuticals North America Inc., Takeda Pharmaceutical Company Limited and Eli Lilly and Company.

Donald Sandidge, Phillip Block and John Allen say they were each prescribed Actos for the long-term maintenance of high blood sugar. Produced joinly by Deerfield, Ill.-based Takeda and Eli Lilly, Actos was first manufactured to be used by patients in 1999. The diabetes drug received FDA approval later that year.

The three men say they took Actos every day as part of their doctors' plans to treat type-2 diabetes. They say it wasn't until they had been taking the drug for several years that they learned the blood-sugar-lowering medication increased the likelihood of developing bladder cancer.

Sandidge, Block and Allen have all been diagnosed with bladder cancer since taking Actos, according to the complaint.

The complaints cite numerous studies documenting an increased risk of bladder cancer in patients taking Actos for more than 12 months. The men, however, claim none of those studies have ever been released or published by researchers or the defendants. They contend Takeda and Eli Lilly intentionally withheld that information to avoid Actos being rejected by the FDA.

An FDA study in late 2010 allegedly found an increased risk of bladder cancer in patients using Actos. The patients say the manufacturers publicly denied the accuracy of the findings and continued to tout Actos as safe for patients.

Based on the results of that 2010 study, the FDA issued a safety announcement in June 2011 that said the "use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer." The information was immediately added to the drug's warning label.

A month after the FDA warning, Sandidge, Block and Allen claim Takeda Limited issued a recall on Actos in France but refused to issue the same recall in the U.S. They say the companies allowed profits to overshadow patient safety. The men claim the diabetes medication accounts for $4.8 billion — approximately 27 percent — of the company's revenue.

Sandidge, Block and Allen accuse the defendants of knowingly "concealing their knowledge of Actos' unreasonably dangerous risks" from patients, their doctors, other consumers and the medical community as a whole. They say they each have bladder cancer as a direct result of the companies' failure to properly share information with patients. Had those risks been disclosed, the men say they would not have taken Actos.

The three men and their wives accuse Takeda and Eli Lilly of negligence, strict liability and negligent failure to warn for allegedly hiding information about the risks posed by Actos. They say the companies were also negligent for failing to improve the medication and reduce the risk posed to patients. They say the manufacturers knew that the risks of Actos far outweighed its benefits yet continued to distribute the drug. They also accuse the defendants of breach of express warranty and violation of Illinois Consumer Protection laws.

The Sandidges, Blocks and Allens say they have endured pain and suffering, economic loss and loss of consortium as a result of the defendants' alleged negligence. The couples are each asking to be awarded more than $50,000 in actual damages along with punitive damages and court costs.

Attorneys Trent B. Miracle and John J. Foley of the Simmons firm in Alton and Paul Hanly and Jayne Conroy of New York are representing the three couples. They demand a jury trial.

If you or a loved one has been injured by Actos causing bladder cancer contact Class Action Lawyer Network today.

Actos Consolidated in Louisiana

Written by Class Action Lawyer on . Posted in Class MDL Class Action News

Takeda Actos Cancer Suits Combined in Louisiana Court, U.S. Panel Rules

Q

Lawsuits against Takeda Pharmaceutical Co. (4502), Asia’s biggest drugmaker, claiming its Actos diabetes drug causes bladder cancer will be consolidated before one judge in federal court in Louisiana, a judicial panel said.

The federal Judicial Panel on Multidistrict Litigation sent the lawsuits to the Western District of Louisiana, in Lafayette, to be overseen by U.S. District Judge Rebecca Doherty. Doherty will coordinate pretrial proceedings, including evidence- gathering.

“Centralization in the Western District of Louisiana will serve the convenience of the parties and witnesses and promote the just and efficient conduct of this litigation,” the panel ruled yesterday. It will also allow “the panel to assign the litigation to an experienced judge who sits in a district in which no other multidistrict litigation is pending.”

The lawsuits claim that patients who use Actos, a prescription drug approved for the use in treating type 2 diabetes, increases the risk of bladder cancer. The plaintiffs also claim that Takeda and co-defendant Indianapolis-based Eli Lilly & Co. (LLY) withheld information about the risk and failed to provide adequate warnings.

Sara Gourley, an attorney for Osaka, Japan-based Takeda, didn’t immediately return a call for comment.

The company said in a September filing that 54 federal lawsuits had been filed by then. Dozens more suits have been added in federal court since, according to court records.

More Patients

Several thousand patients have contacted plaintiffs lawyers about filing such suits, Paul J. Pennock, a New York-based lawyer representing former users of the drug, said in an interview last month.

U.S. regulators found in June that an analysis of a Takeda- sponsored study showed some users of Actos, the world’s best- selling diabetes medication, faced an increased risk of developing the potentially fatal disease. The federal lawsuits were all filed in July or later, the federal panel said in yesterday’s ruling.

Takeda officials this year pulled Actos, its top-selling drug, off the market in Germany and France after it was linked to an increased cancer risk.

Takeda had asked the panel to consolidate the cases in the Northern District of Illinois in Chicago, near the headquarters of five of the company’s units, or the Louisiana court as an alternative. Lawyers for plaintiffs disagreed on the choice of venue, proposing six other courts as well as those in Chicago and Lafayette.

The lawsuits are consolidated in In Re: Actos Products Liability Litigation, MDL 2299, U.S. District Court, Western District of Louisiana (Lafayette).

New Actos Drug Delayed By FDA, Actos and Bladder Cancer

Written by Class Action Lawyer on . Posted in Drug Warnings

Following Actos Warning, FDA Delays Review of New Actos Combined Drug

Following Actos Warnings, FDA Delays Review of New Takeda Diabetes Drug. As is known Actos is known to cause bladder cancer in Type 2 Diabetics with long term use.

With  Takeda Pharmaceuticals already facing many  Actos lawsuits, the U.S. Food and Drug Administration has decided to delay its review of a new type 2 diabetes drug being developed by Takeda Pharmaceutical Company. July 2011, Takeda re-filed an application to have the drug approved by the FDA and eventually have the drug made available to the public. The new data submitted to the FDA includes information about a cardiovascular outcomes trial. The new drug would be the first in the United States to have both a thiazolidinedione and a DPP-4 inhibitor in a single pill. Currently, Aloglitin is sold in other countries and has been approved by some regulators overseas

The U.S. Food and Drug Administration has notified drug partner Takeda Pharmaceuticals that review of investigational diabetes drug alogliptin has been delayed and an approval decision is now expected by April 25, 2012. The delay also affects the fixed-dose combination drug alogliptin/pioglitazone. Regulators had previously expected to make a decision by Jan. 25, 2012.

According to a release from the company, the FDA has decided to pause the review of the investigative type 2 diabetes therapy alogliptin as well as the combination medication alogliptin/pioglitazone. Pioglitazone is the active chemical in the brand name medication Actos.

With the delay having been announced, the new Prescription Drug User Fee Act (PDUFA) action date has reportedly now been set for April 25, 2012, after the federal agency initially assigned a date of January 25, 2012, according to the release from Takeda.

Despite the delay, David Recker, senior vice president of clinical science for Takeda Global Research & Development Center in the U.S., said in a statement that the company still supported the medication's effectiveness.

"Takeda is confident in alogliptin and alogliptin/pioglitazone as potential therapeutic options for the millions of patients living with type 2 diabetes," Recker noted. "We will work closely with the FDA to determine the appropriate next steps, and are dedicated to continuing our efforts to bring these important therapies to market in the U.S."

In the release, the company disclosed that alogliptin is a highly selective dipeptidyl peptidase IV inhibitor (DPP-4i) designed to treat patients suffering from type 2 diabetes when supplemented with the proper diet and exercise.

The drug reportedly works by slowing the inactivation of incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide), which are instrumental in the regulation of blood sugar levels, the company said.

Takeda also added that it has not adjusted its fiscal outlook as a result of the delay in the drug's review, according to the release.

Still, the Japanese drugmaker has been hit hard by the recent spate of Actos lawsuits stemming from Actos warnings being handed down in the U.S. and Europe. Actos, which is also designed to treat patients with type 2 diabetes, has been linked in studies to the potential increased risk of bladder cancer, particularly among patients who have been using the medication for an extended period of time.

As a result of these Actos warnings that have been handed down by the FDA and the European Medicines Agency, Takeda now faces a number of lawsuits across the U.S., and the drugmaker recently experienced a dip in first-half operating profit.

According to Reuters, the requests from the European Medicines Agency and the FDA to add warnings to the medication's labels have had a significant impact on Actos' sales. Sales of the drug fell 13 percent in the six month-period ending September 30. This, coupled with the strong yen, has significantly dented Takeda's profits.

Doctors and patients are becoming increasingly wary of the medication as the number of Actos lawsuits pile up. Thus far, there have been lawsuits filed in states such as Illinois and Louisiana, with plaintiffs often claiming the drugmaker purposely concealed the bladder cancer side effects of the drug at the expense of patients.

While these Actos lawsuits largely center on the risk of bladder cancer, Actos has also been linked to the eye disease macular edema, which is a leading cause of blindness in older adults, according to reports.

ACTOS can cause your body to keep extra fluid (fluid retention), which leads to swelling (edema) and weight gain. Extra body fluid can make some heart problems worse or lead to heart failure. A new study presented in June at the American Diabetes Association’s (ADA) annual meeting suggested that Actos can also lead to vision loss or blindness. Was this really new information or not? I did a little bit more research on Actos and blindness and was shocked to see that back in April 2009, the American Journal of Ophthalmology also posted a “recent study” where nearly 1,000 patients developed Diabetic Macular Edema (DME) after taking Actos. Even more shocking was a 2003 study that showed results of a retrospective study that also indicated that Actos could result in DME. According to that article, presented at the annual meeting of the American Academy of Ophthalmology, patients in that study had macular edema.

Actos is a member of a class of drugs known as thiazolidinediones, which have been linked to bladder cancer,” the US Drug Watchdog said in a released statement. “Actos side effects include increased risk of congestive heart failure, and an increased risk for bladder cancer.

 Network Actos Helpline has been taking calls from people with signs of bladder cancer form Actos as well as families for Wrongful death of a loved one from bladder cancer due to Actos. Actos lawyers are filing lawsuits against TAKEDA Pharmaceuticals for Actos. In light of complications from Actos Takeda appears to be taking a very ambitious step with this new drug. If approved Ibelieve it will be a very hard sell to physicians given the warnings for Actos. If you or a loved one has complications due to Actos contact the Actos Helpline

Class Action lawyer Network Actos lawyers re filing Lawsuits on behalf of clients with complications from Actos

Type 2 Diabetics, Actos and Bladder Cancer

Written by Class Action Lawyer on . Posted in Drug Lawsuits

  Type II  Diabetics are showing side effects from actos. There have been significant reports showing the relationship between actos and bladder cancer. It is alleged that the manufacturer should have been aware and warned Type 2 Diabetics about actos side effects.
      ACTOS is a prescription drug used with diet and exercise to improve blood sugar (glucose) control in adults with type ii diabetes. ACTOS is not for patients with type 1 "juvenile" diabetes or diabetic ketoacidosis. It is impossible for a patient to assess the safety of a drug before taking it.. Helpless and vulnerable patients rely on others such as drug manufacturers,physicians and pharmacists to help make the right decision regarding the medications they take. While many drugs do what they are intended to do and help relieve symptoms improve quality of life, some drugs are defective and dangerous. Patients trust the physicians and when a "good" drug turns bad they do not know where to turn. Some groups have a higher risk for developing type 2 diabetes than others. Type 2 diabetes is more common in the aged population.Caregivers must step up to assist their older patients who are affected by actos Being the primary caregiver for a person who has diabetes can take an emotional toll. A diabetes caregiver may be the one taking ownership of his or her loved one's diabetes if the person with diabetes doesn't or can't. There may be feelings of guilt,that is why they must step up on behalf of their patients and loved ones to protect them. Actos has been shown to have serious side effects including heart problems and bladder cancer. EHealthMe conducted a study on August 17, 2011 regarding the side effects of taking Actos and the bladder cancer risk. According to the report, 22,512 reported side effects when taking Actos and 0.22% have bladder cancer. The largest concentration (approx. 43%) were using Actos between 2-5 years before having Bladder Cancer with the next largest concentration (approx. 29%) used Actos between 1-6 months. Older populations and many minority groups  are effected by these new findings.

TYpe II Diabetes Information

          Type 2 diabetes, also known as adult-onset or noninsulin-dependent diabetes, is a chronic condition that affects the way your body metabolizes sugar (glucose), your body's main source of fuel.Insulin is a hormone that regulates the movement of sugar into your cells.With type 2 diabetes, your body either resists the positive effects of insulin or doesn't produce enough insulin to maintain a normal glucose level. Untreated, type 2 diabetes can be life-threatening. Complications of Diabetes Diabetes can lead to high blood sugar levels, a condition called hyperglycemia. Over a long period of time, hyperglycemia damages the retina of the eye, the kidneys, the nerves, and the blood vessels.Damage to the retina from diabetes (diabetic retinopathy) is a leading cause of blindness.Damage to the kidneys from diabetes (diabetic nephropathy) is a leading cause of kidney failure. Damage to the retina from diabetes (diabetic retinopathy) is a leading cause of blindness.Damage to the nerves from diabetes (diabetic neuropathy) is a leading cause of foot wounds and ulcers, which frequently lead to foot and leg amputations.Damage to the nerves in the autonomic nervous system can lead to paralysis of the stomach (gastroparesis), chronic diarrhea, and an inability to control heart rate and blood pressure during postural changes
Ads by Google
           Damage to the nerves in the autonomic nervous system can lead to paralysis of the stomach (gastroparesis), chronic diarrhea, and an inability to control heart rate and blood pressure during postural changes.Diabetes accelerates atherosclerosis, (the formation of fatty plaques inside the arteries), which can lead to blockages or a clot (thrombus). Such changes can then lead to heart attack, stroke, and decreased circulation in the arms and legs. Damage to the nerves from diabetes (diabetic neuropathy) is a leading cause of foot wounds and ulcers, which frequently lead to foot and leg amputations(peripheral vascular disease).Damage to the nerves from diabetes (diabetic neuropathy) is a leading cause of foot wounds and ulcers, which frequently lead to foot and leg amputations.Damage to the nerves in the autonomic nervous system can lead to paralysis of the stomach (gastroparesis), chronic diarrhea, and an inability to control heart rate and blood pressure during postural changes. Diabetes accelerates atherosclerosis, (the formation of fatty plaques inside the arteries), which can lead to blockages or a clot (thrombus). Such changes can then lead to heart attack, stroke, and decreased circulation in the arms and legs (peripheral vascular disease).As of June 10, 2011 doctors in France and Germany have been instructed not to proscribe the drug Actos to their  Type II Diabetic patients and the drug Actos has actually been removed from pharmacy shelves. The reason for these actions is because recent studies have shown that an patients who use the drug Actos to treat their Type II Diabetes by using Actos are more likely to contract bladder cancer.
               What makes this fact more difficult to accept is that it appears that the incidence of Bladder Cancer in Type II Diabetics using the drug Actos, was known to the drug manufacturer Takeda, Inc. in the clinical trials However, even though, Takeda, Inc. apparently knew that the drug Actos would cause bladder cancer, it still marketed and sold 2.3 million prescriptions for the drug Actos in the United States in one year alone. 2010. The active ingredient in Actos, Pioglitazone, is also used in ActoPlus met, ActoPlus met XR and Duetac to treat Type 2 Diabetes.
              On June 15, 2011, the FDA issued an urgent health warning to users and prescribers of the drug Actos acknowledging the recent statistical data that shows up to a 40% increase in risk for bladder cancer in users of Actos. The studies further show that the risk of bladder cancer increases with higher dosages and longer courses of treatment with Actos.In one study involving more than 193,000 patients with diabetes, patients taking Actos were on the drug for an average of two years, the FDA said. "Compared to never being exposed to pioglitazone, a duration of pioglitazone therapy longer than 12 months was associated with a 40 percent increase in risk [for bladder cancer]," the agency said. A French study examined cancer rates in some 155,000 people taking Actos in France from 2006 to 2009 and 1.3 million other diabetics who were not receiving the drug. The study found about a 22 percent higher risk of bladder cancer in those taking Actos compared with diabetics taking other drugs. The bladder cancer risk was highest in those receiving a cumulative Actos dosage of 28,000 mg or more during the study period.Patients taking the diabetes drug Actos for more than a year may have an increased risk of bladder cancer, according to an FDA interim review of an ongoing epidemiological study.After the health warning was issued the FDA will now require that these recent findings and risks be included in warnings attached to the drug packaging and future marketing materials. The FDA is also going to continue monitor the data being released by various.  So  far, Actos remains available to consumers in the United States despite these risks


Class Action Lawyer Network  Actos team is ready to help you. If you or a loved one has been injured by actos call now and speak to our medical MSW. As a caregiver for someone who may be a victim of Actos you should call us immediately and get the facts.